Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446582 · ClinicalTrials.gov registry record
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
A clinical trial of Age-Related (Dry) Macular Degeneration, sponsored by AI-Spectral.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT07446582 is a study of Age-Related (Dry) Macular Degeneration that is actively recruiting participants, run by AI-Spectral. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07446582, a study of Age-Related (Dry) Macular Degeneration, is actively recruiting participants, sponsored by AI-Spectral.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are: * Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians? * Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians? Participants' eyes will be imaged by MSI-120 and their images will be analyzed for AMD biomarkers by both DeepMSI AI and retina specialists independently. Researchers will compare retina image analysis from DeepMSI AI with ground truth (clinicians' interpretations) to see if AI achieves equivalency in sensitivity and specificity.
Conditions Studied
Interventions
- DEVICE Retina imaging device (MSI-120) and AI (DeepMSI AI)
Study Locations (1)
New Jersey
- Contact Lens & Vision - Woodbridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2026-09-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446582
The ClinicalTrials.gov registry entry for NCT07446582 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AI-Spectral, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-Related (Dry) Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Retina imaging device (MSI-120) and AI (DeepMSI AI) is the first listed.
NCT07446582 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07446582 about?
NCT07446582 is a clinical study titled "Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection". The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are: * Does DeepMSI AI detect AMD...
What is the current status of trial NCT07446582?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2026-02-01. Estimated completion is 2026-09-05.
What conditions does trial NCT07446582 study?
This clinical trial studies the following conditions: Age-Related (Dry) Macular Degeneration.
What interventions are being tested in trial NCT07446582?
The interventions under investigation include: Retina imaging device (MSI-120) and AI (DeepMSI AI) (DEVICE).
Who is sponsoring clinical trial NCT07446582?
This trial is sponsored by AI-Spectral, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07446582 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-Related (Dry) Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.